A novel MGB probe-based assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPMI (nucleophosmin) exon 12 mutations

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

DVOŘÁKOVÁ Dana OHLÍDALOVÁ D. POSPÍŠILOVÁ J. LENGEROVÁ Martina MAYER Jiří

Year of publication 2008
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Insertions into exon 12 of NPM1 gene represent the most frequent molecular aberration in the subgroup of patients with AML otherwise showing normal karyotype. Therefore, NPM1 mutations may be used as a marker for quantification of minimal residual disease (MRD). Here we propose highly sensitive and reproducible MGB probe-based method for MRD.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.